Control of Mutagenic Impurities: Survey of Pharmaceutical Company Practices and a Proposed Framework for Industry Alignment

2021 ◽  
Vol 25 (4) ◽  
pp. 831-837
Author(s):  
Christopher J. Borths ◽  
Mark D. Argentine ◽  
John Donaubauer ◽  
Eric L. Elliott ◽  
Jared Evans ◽  
...  
Keyword(s):  
Pharmaceutical Company

Pharmacoeconomic considerations in pharmaceutical company promotions

1994 ◽  
Vol 3 (12) ◽  
pp. 1034-1035 ◽  
Author(s):  
A. O. Goldstein
Keyword(s):  
Pharmaceutical Company

Offer of methods for minimizing key investment risks of “R-Pharm” JSC

2020 ◽  
Vol 17 (1) ◽  
pp. 58-67
Author(s):  
N. A. Kabanova ◽  
I. K. Alekseeva
Keyword(s):  
Strategic Planning ◽  
Pharmaceutical Company ◽  
Simulation Modeling ◽  
Return On Investment ◽  
System Analysis ◽  
Social Orientation ◽  
Pharmaceutical Companies ◽  
The Subject ◽  
High Degree

The article is devoted to the assessment of potential investment risks of the pharmaceutical company “R-Pharm” JSC with the aim of identifying the highest priority risks and developing methods for minimizing them. The relevance of the study is determined by the fact that the pharmaceutical business is characterized by a high degree of social orientation and annually invests $ 140 billion in the development of production and research, which determines the need for a risk-based approach to ensure the return on investment. The subject of this article is the investment risks of pharmaceutical companies, and the subject of research is the domestic pharmaceutical company “R-Pharm”. In order to assess the potential investment risks of “R-Pharm” JSC, the authors used elements of simulation modeling and system analysis. The proposed methods to minimize key investment risks are aimed at improving the efficiency of investment activities and is recommended as an element of the strategic planning of the company.

Investigation Of Over The Counter (Otc ) Pharmaceutical Brands Prefered By New Age Indian Women

2019 ◽  
Vol 118 (4) ◽  
pp. 1-15
Author(s):  
Dr.G. Madhumita ◽  
Dr.G. Rajini ◽  
Dr.B. Subisha
Keyword(s):  
Pharmaceutical Company ◽  
Medical Practitioner ◽  
New Age ◽  
The Other ◽  
Pharmaceutical Companies ◽  
Brand Preference ◽  
Over The Counter ◽  
Indian Women ◽  
Prescription Medicines ◽  
Otc Medicines

The study investigates the preference of OTC Medicines among the pharmaceutical brand.OTC Medicines means medicines lawfully permitted to sell  “Over the Counter”, i.e. devoid of the prescription of a Registered Medical Practitioner. In India, although the expression has no lawful acknowledgment, all the medicines that are not incorporated in the list of ‘prescription only medicines’ are measured as non-prescription medicines (or OTC Medicines).Pharmaceutical over the counter products (OTC) be the medicines which can be sold without prescription. Also termed as “Non Prescription Medicines” discussed by Arti(2010).This article talks about top pharmaceutical company brands Aventis Pharma, GlaxoSmithKline, Surya Pharma, Torrent Pharma,Glenmark,Divis Labs,Biocon, Orchid Chemical, Abbott Indi, Sterling Bio, Alembic Pharma etc, the brand preference of New Age Indian Women. A 736 questionnaire was composed of different age and different New Age Indian Women in around Urban :Chennai ;Semi Urban :Neyveli ; Rural :Soolurpet ;Tirupur. The findings of the study shows that the highest preferred generic brand is balms,  Medicines chosen  for fever is Crocin, Idoex  is most ideal pain blams, volini spray is also most preferred brand, ENO is ideal Antacid brand, Sadiron is another chosen brand for cough and cold, the other brands are Metfal SPS, Johnson, Revital are the other favored brands. The study will be a great instrument for the pharmaceutical companies brands to understand today’s New Age Indian Women.

PENGARUH DEBT TO TOTAL ASSET RATIO DAN TOTAL ASSET TURN OVERTERHADAP EARNING PERSHARE PADA PERUSAHAAN SUBSEKTOR FARMASI YANG TERDAFTAR DI BURSA EFEK INDONESIA

2018 ◽  
Author(s):  
STIM Sukma
Keyword(s):  
Data Processing ◽  
Pharmaceutical Company ◽  
Stock Exchange ◽  
Total Asset ◽  
Coefficient Of Determination ◽  
Simultaneous Test ◽  
Earnings Per Share ◽  
Regression Test ◽  
Asset Turnover ◽  
Convenience Sampling

The purpose of this study was to determine whether there is influence of debt to total assets ratio and total asset turnover to earnings per share in the sub-sector pharmaceutical company listed on the Indonesia Stock Exchange. Samples were taken throughout the pharmaceutical company listed on the Indonesia Stock Exchange for the years 2010 to 2015, sampling using a convenience sampling is sampling based on the desire of researchers. Analysis of data using multiple regression test the accuracy of the model (the classical assumption), hypothesis testing using the coefficient of determination (R ²), partial test (t test) and a simultaneous test (f test), while the data processing using SPSS. The results showed that test the coefficient of determination (R ²) DAR and TATO variable able to explain the existence of the variable Earning Per Share, besides partially and simultaneously DAR and TATO negative and not significant to Earning Per Share.Keywords: Debt to total assets ratio, total asset turnover and earnings per share.

THE INFLUENCE OF NET PROFIT MARGIN AND CURRENT RATIO ON STOCK PRICE

2017 ◽  
Vol 9 (2) ◽  
pp. 37-43
Author(s):  
Sri Dewi Anggadini ◽  
Eva Tarsiah
Keyword(s):  
Data Analysis ◽  
Pharmaceutical Company ◽  
Stock Price ◽  
Stock Exchange ◽  
Profit Margin ◽  
Pharmaceutical Companies ◽  
Analysis Method ◽  
Current Ratio ◽  
Financial Reports ◽  
Net Profit

 This research have purpose to examine empirically the effect on Net Profit Margin and Liquidity (Current Ratio) to Stock Price on Sub Sector Pharmaceutical Company Listed on IndonesiaStock Exchange Period 2012-2016. The problems that occur in Sub Sector Pharmaceutical Companyis the decrease of Stock Price but not followed by the increase of Net Profit Margin. Then the companyhas descreased Stock Price but not followed by the increase of Liquidity (Current Ratio). The research uses descriptive verification analysis method with population 10 companies from Sub Sector Pharmaceutical Companies. Sample selected by using purposive sampling, so thesample obtained to 8 companies with 40 financial reports from Sub Sector Pharmaceutical CompanyListed in Indonesia Stock Exchange Period 2012-2016. Technical of data analysis is multiple linearregression with SPSS 16.0 version as the application.  The result of the analysis showed that Net Profit Margin has positive and significant effect to Stock Price, and Liquidity which measured by Current Ratio has Positive dan significant effect toStock Price.

Effects of Disclosure Laws on Pharmaceutical Company Payments to Physicians

2012 ◽  
Author(s):  
Daniel L. Chen ◽  
S. Eric Reinhart ◽  
Glen Taksler
Keyword(s):  
Pharmaceutical Company ◽  
Disclosure Laws

scholarly journals Towards Implementation of Big Data Concepts in a Pharmaceutical Company

2020 ◽  
Vol 10 (1) ◽  
pp. 343-356
Author(s):  
Snezana Savoska ◽  
Blagoj Ristevski
Keyword(s):  
Information Technology ◽  
Big Data ◽  
Data Analysis ◽  
Pharmaceutical Company ◽  
Big Data Analytics ◽  
Structured Interviews ◽  
Holistic View ◽  
Analysis Methodology ◽  
Decision Making Processes ◽  
Research Demands

AbstractNowadays, big data is a widely utilized concept that has been spreading quickly in almost every domain. For pharmaceutical companies, using this concept is a challenging task because of the permanent pressure and business demands created through the legal requirements, research demands and standardization that have to be adopted. These legal and standards’ demands are associated with human healthcare safety and drug control that demands continuous and deep data analysis. Companies update their procedures to the particular laws, standards, market demands and regulations all the time by using contemporary information technology. This paper highlights some important aspects of the experience and change methodology used in one Macedonian pharmaceutical company, which has employed information technology solutions that successfully tackle legal and business pressures when dealing with a large amount of data. We used a holistic view and deliverables analysis methodology to gain top-down insights into the possibilities of big data analytics. Also, structured interviews with the company’s managers were used for information collection and proactive methodology with workshops was used in data integration toward the implementation of big data concepts. The paper emphasizes the information and knowledge used in this domain to improve awareness for the needs of big data analysis to achieve a competitive advantage. The main results are focused on systematizing the whole company’s data, information and knowledge and propose a solution that integrates big data to support managers’ decision-making processes.

scholarly journals Internal Supply Chain Digital Twin of a Pharmaceutical Company

2020 ◽  
Vol 53 (2) ◽  
pp. 10797-10802
Author(s):  
João A.M. Santos ◽  
Miguel R. Lopes ◽  
Joaquim L. Viegas ◽  
Susana M. Vieira ◽  
João M.C. Sousa
Keyword(s):  
Supply Chain ◽  
Pharmaceutical Company ◽  
Digital Twin

scholarly journals Strategic account management as a value co-creation selling model in the pharmaceutical industry

2017 ◽  
Vol 32 (2) ◽  
pp. 310-325 ◽  
Author(s):  
Francois Pilon ◽  
Elias Hadjielias
Keyword(s):  
Pharmaceutical Industry ◽  
Pharmaceutical Company ◽  
Value Added ◽  
Pharmaceutical Companies ◽  
Design Data ◽  
Content Type ◽  
Qualitative Research Design ◽  
Account Management ◽  
A Value ◽  
Key Accounts

Purpose This study aims to explore the dynamics enabling strategic account management (SAM) to function as a value co-creation selling model in the pharmaceutical industry. Design/methodology/approach Using an inductive qualitative research design, data are collected within 11 industry customers in Canada. This work focuses on hospitals as strategic accounts of pharmaceutical companies, exploring SAM value co-creation in the “hospital-pharmaceutical company” relationship. Findings The findings suggest the presence of two key dimensions that can enable a value co-creation SAM model in the hospital-pharmaceutical relationship: “customer-tailored value-added initiatives” and “relationship enhancers”. Customer-tailored value-added initiatives explain the activities that are central to the hospital-pharmaceutical company relationship and can lead to the provision of value added that is unique to the hospital. Relationship enhancers explain the activities that can help strengthen hospital-pharmaceutical company relations in the pursuit of enhanced value-added interactions between the two parties. The research demonstrates a cyclical relationship between “customer-tailored value-added initiatives” and “relationship enhancers”, leading to value co-creation through a SAM model. Practical implications The study informs pharmaceutical industry practitioners on how to improve their value proposition through new, more sustainable selling practices. It offers information on implementing a value co-creation SAM model, which can enable pharmaceutical companies to sustain long-lasting value-added relationships with key accounts such as hospitals. Originality/value The study contributes to the field of SAM by conceptualizing SAM as a value co-creation system. It introduces new knowledge in pharmaceutical marketing by offering empirical insight on the applicability and use of SAM in the hospital-pharmaceutical company dyad.

Sign in / Sign up

Export Citation Format

Share Document